Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
4 Stocks With Strong Interest Coverage Ratios to Buy in June 2025
11:45am, Tuesday, 03'rd Jun 2025
STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
Halozyme to Participate at Upcoming Investor Conferences
04:05pm, Wednesday, 28'th May 2025
SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participa
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
01:51pm, Wednesday, 28'th May 2025
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:46am, Wednesday, 28'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) to
New Strong Buy Stocks for May 28th
05:40am, Wednesday, 28'th May 2025
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
12:26pm, Wednesday, 14'th May 2025
STRL, AXS, MOH & HALO's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
10:50am, Tuesday, 13'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
01:50pm, Monday, 12'th May 2025
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:45am, Monday, 12'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
10:44am, Monday, 12'th May 2025
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key grow
S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points
11:47am, Saturday, 10'th May 2025
Visa has topped a buy point, while fellow S&P 500 component Insulet gapped out of a base, leading five stocks on this weekend watchlist.
Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
01:00pm, Friday, 09'th May 2025
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:55am, Thursday, 08'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
01:15pm, Wednesday, 07'th May 2025
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025.
